Per Editor: Yang Huan
Enterprise Lab Image source: Courtesy of Chengdu High-tech Zone
Recently, Chengdu Qi Carbon Technology Co., Ltd. released its self-developed nanopore gene sequencer QNome-3841 and supporting chips and reagents, and announced the completion of its production base in Chengdu Tianfu International Bio-City. According to reports, the research and development of nanoporous gene sequencers is a technical breakthrough spanning biochemistry, biochips, electronic circuits, artificial intelligence and other disciplines.
In addition, the company's production base was officially completed, and the new product will be mass-produced here. At that time, the first batch of domestically commercially deliverable nanoporous gene sequencers and their supporting chips and reagent consumables will be produced and sold in Chengdu. The new production site plans to put into production products including library building kits, sequencing kits, biochips, nanoporous gene sequencers, etc. After being put into use, 2,000 sets of nanoporous gene sequencers and 1 million copies of supporting sequencing chips and kits will be produced every year.
In this regard, the relevant person in charge of Chengdu Tianfu International Bio-City said: "The completion of the enterprise production base and the formal commercialization of new products will accelerate the development of the biotechnology industry ecology in Chengdu and even in China, and provide benchmark samples for the development of related industries." ”
It is reported that Chengdu Tianfu International Bio-City is jointly built by Chengdu High-tech Zone and Shuangliu District. Up to now, Chengdu Tianfu International Bio-City has gathered 27 innovative public service platforms, introduced 170 projects such as Sinopharm Zhongsheng Blood Products Headquarters and Industrialization Base, Luye Life Science Industrial Park, Dongfulong Biopharmaceutical Equipment Innovation R&D Production Base and Southwest Operation Center, with a total investment of more than 110 billion yuan, and introduced and cultivated 134 new drug varieties.
Daily economic news
![In the 100-billion-level pharmaceutical industry cluster, how to make up for the "key link" of the supply chain, capital chain and innovation chain?[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)